Latest revenue
—
as of 2025-03-31
Latest net income
$-11.4M
as of 2025-03-31
Net margin
—
as of 2025-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think AMIX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $4.3M
- Enterprise value
- $-4.5M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.51×
- Dividend yield
- 0.0%
- 52-wk high
- $2.64
- 52-wk low
- $0.20
- Beta
- —
- Shares out
- 11.4M
5-year trend
What this company does
Item 1. Business Overview We are a development-stage medical device company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Our first-in-class technology platform includes a catheter-based microchip-enabled sensing array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies. We are initially developing our technology for patients with pancreatic cancer, a condition that can cause debilitating pain and needs a more effective solution. However, we believe our technology constitutes a platform with the potential to address dozens of indications in a range of areas…
AI summary unavailable — showing raw filing excerpt
Generated from AMIX's filing dated 2025-05-29
Key risks
Item 1A. Risk Factors. Summary of Risk Factors: Below is a summary of the principal factors that make an investment in our Company speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary and other risks that we face, can be found below, after this summary, and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings with the SEC, before making an investment decision in our securities. Risks Related to Our Overall Business • Factors raise substantial doubt about our ability to continue as a going concern; • We have no approved…
AI summary unavailable — showing raw filing excerpt
Generated from AMIX's filing dated 2025-05-29
Profitability
Return on equity
-140.9%
30.3%Return on assets
-116.4%
29.0%Leverage
Debt / equity
0.21×
9.6%Long-term debt / equity
0.00×
100.0%Debt / assets
17.4%
8.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | — | — | $-3.3M | -20.2% | — |
Q3 2025 2025-09-30 | — | — | $-7.5M | -165.4% | — |
Q2 2025 2025-06-30 | — | — | $-3.3M | -23.6% | — |
Q1 2025 2025-03-31 | — | — | $-3.2M | +41.0% | — |
Q4 2024 2024-12-31 | — | — | $-2.7M | +12.9% | — |
Q3 2024 2024-09-30 | — | — | $-2.8M | +53.5% | — |
Q2 2024 2024-06-30 | — | — | $-2.7M | -212.0% | — |
Q1 2024 2024-03-31 | — | — | $-5.4M | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on AMIX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AMIX
Institutional value
$61.7K
Total shares held
144.7K
Distinct holders
8
-9 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Mariner, LLC | 52.9K | $25.9K | -233 (-0.4%) | Trimmed |
| 2 | UBS Group AG | 33.5K | $13.1K | +33.4K (+26275.6%) | Added |
| 3 | LPL Financial LLC | 31.4K | $12.3K | +0 (+0.0%) | No change |
| 4 | BANK OF MONTREAL /CAN/ | 25.0K | $9.8K | +0 (+0.0%) | No change |
| 5 | PNC Financial Services Group, Inc. | 1.6K | $619 | +0 (+0.0%) | No change |
| 6 | Investors Research Corp | 200 | $78 | -20 (-9.1%) | Trimmed |
| 7 | Key Capital Management, INC | 10 | $4 | +0 (+0.0%) | No change |
| 8 | Farther Finance Advisors, LLC | 10 | $4 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AMIX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.